Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
EDQM has also issued a Certificate of Suitability for Allopurino
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
HaystackAnalytics is engaged in the business of developing genomic analysis software
Subscribe To Our Newsletter & Stay Updated
